MANATEE

Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 Diabetes (MANATEE-T1D)

A solid, uniform light blue color fills the entire image without any patterns, objects, or text visible.

Study Description

IRB #

STUDY00005088

NCT #

NCT05065372

Principal Investigator

Kalie Tommerdahl

Study Location

Seattle Children’s Hospital

This is a double blinded placebo trial to learn about the health effects of combining two treatments, the automated insulin delivery system and metformin, for people with type 1 diabetes aged 12-25. Participants on multiple daily insulin injections will have their body composition, cardiovascular health, and insulin sensitivity twice four months apart(involves placement of two IVs). Only youth on pump systems will take metformin or a placebo during the four months period (in addition to the same assessments as the other group).

Learn More

FAQ Title

Learn more about how you can contribute to important research by volunteering for MANATEE.

Who Can Participate?

Inclusion Criteria:

Youth between the ages of 12-25 with 1 diabetes, are not taking any diabetes control medications other than insulin, and have been steady on their insulin delivery system for 6 month.

Contact Study Team

Interested? 👉 Click here to contact the study team

Contact Name: Kevin Bocek

Phone Number: 206-884-1982

Email: kevin.bocek@seattlechildrens.org

Contact the Study Team - MANATEE

Name(Required)

First Last

Phone(Required)

Email(Required)

Enter Email Confirm Email

Comments(Required)

Preferred Method of Contact (email, phone call, text)